Effects of the Antioxidant Agent Tempol on Periapical Lesions in Rats with Doxorubicin-induced Cardiomyopathy

被引:29
|
作者
Brilhante Wolle, Carlos Frederico [1 ]
Zollmann, Luciana de Aguiar [2 ]
Etges, Adriana [4 ]
Vitalis, Graciela Schneider [5 ]
Leite, Carlos Eduardo [3 ]
Campos, Maria Martha [1 ,3 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Sch Dent, BR-90619900 Porto Alegre, RS, Brazil
[2] Pontificia Univ Catolica Rio Grande do Sul, Fac Pharm, BR-90619900 Porto Alegre, RS, Brazil
[3] Pontificia Univ Catolica Rio Grande do Sul, Inst Pharmacol & Toxicol, BR-90619900 Porto Alegre, RS, Brazil
[4] Univ Fed Pelotas, Sch Dent, Dept Oral Pathol, Pelotas, Brazil
[5] Ctr Univ Franciscano, Nano Sci Coll, Santa Maria, RS, Brazil
关键词
Antioxidant therapy; cardiomyopathy; doxorubicin; periapical periodontitis; rats; PERMEABLE RADICAL SCAVENGER; (-)-EPIGALLOCATECHIN GALLATE; INTRACANAL MEDICATION; RODENT MODEL; GREEN TEA; EXPRESSION; PULP; MECHANISMS;
D O I
10.1016/j.joen.2011.11.007
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Cardiovascular diseases have been associated with increased risk of endodontic complications. This study evaluated the effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy in comparison with control animals. Methods: Forty male Wistar rats were divided into 4 groups: (1) naive rats orally treated with saline solution (10 mL/kg, during 21 days after periapical lesion induction); (2) naive rats treated with tempol (30 and 50 mg/kg, during 21 days after periapical lesion induction) by oral pathway; (3) rats with doxorubicin-induced cardiomyopathy treated with saline solution by oral route (10 mL/kg, from day 3 to day 10 after initiating treatment with doxorubicin); and (4) rats with doxorubicin-induced cardiomyopathy orally treated with tempol (30 and 50 mg/kg, from day 3 to day 10 after initiating treatment with doxorubicin). Periapical lesions were induced on the first right mandibular molar tooth. After 21 days of apical periodontitis induction, the animals were killed, and the mandibles were collected for radiographic and histologic analysis. Results: The oral administration of tempol (50 mg/kg) was able to significantly prevent the establishment of periapical lesions in either control animals or rats submitted to the model of doxorubicin-induced cardiomyopathy, according to radiographic and histologic evaluation. Nevertheless, the protective effects of tempol were virtually greater in control animals in comparison with doxorubicin-treated rats, as indicated by histologic inflammatory assessment, which might be related to the increased production of free radicals under cardiomyopathy. Conclusions: We provide novel evidence on the beneficial systemic effects of the antioxidant tempol on apical periodontitis in both control animals and rats with doxorubicin-elicited cardiomyopathy. (J Endod 2012;38:191-195)
引用
收藏
页码:191 / 195
页数:5
相关论文
共 50 条
  • [1] Cardiotoxic effects of naproxen in doxorubicin-induced cardiomyopathy in rats
    Ahmad, R.
    Pillai, K. K.
    Dubey, K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 110 - 110
  • [2] Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats
    Matsui, H
    Morishima, I
    Numaguchi, Y
    Toki, Y
    Okumura, K
    Hayakawa, T
    LIFE SCIENCES, 1999, 65 (12) : 1265 - 1274
  • [3] Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats
    Rashikh, Azhar
    Najmi, Abul Kalam
    Akhtar, Mohammad
    Mahmood, Danish
    Pillai, Krishna K.
    Ahmad, Shibli J.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2011, 30 (02) : 102 - 109
  • [4] Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats
    Fadillioglu, E
    Erdogan, H
    Sögüt, S
    Kuku, I
    JOURNAL OF APPLIED TOXICOLOGY, 2003, 23 (01) : 71 - 74
  • [5] Naproxen aggravates doxorubicin-induced cardiomyopathy in rats
    Pathan, Rahila Ahmad
    Singh, Bhulan Kumar
    Pillai, K. K.
    Dubey, Kiran
    INDIAN JOURNAL OF PHARMACOLOGY, 2010, 42 (01) : 44 - 49
  • [6] Phenomapping for classification of doxorubicin-induced cardiomyopathy in rats
    Pajovic, Vladislav
    Kovacshazi, Csenger
    Kosic, Marija
    Vasic, Marko
    Dukic, Ljiljana
    Brenner, Gabor B.
    Giricz, Zoltan
    Bajic, Dragana
    Ferdinandy, Peter
    Japundzic-Zigon, Nina
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 423
  • [7] Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats
    Alanazi, Abeer
    Fadda, Laila
    Alhusaini, Ahlam
    Ahmad, Rehab
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2020, 34 (07)
  • [8] CHRONIC DOXORUBICIN-INDUCED CARDIOMYOPATHY AND CARDIAC ANTIOXIDANT DEFENSE
    SAMII, SM
    FOLLANSBEE, MH
    SCADUTO, RC
    FASEB JOURNAL, 1995, 9 (04): : A895 - A895
  • [9] Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats
    Amir Abbas Farshid
    Esmaeal Tamaddonfard
    Naeime Simaee
    Sanam Mansouri
    Sima Najafi
    Siamak Asri-Rezaee
    Hossein Alavi
    Cardiovascular Toxicology, 2014, 14 : 153 - 161
  • [10] Cardioprotective effects of Ecklonia cava polyphenol on doxorubicin-induced cardiomyopathy in rats
    Jeon, H. K. Hui Kyung
    Ahn, H. S.
    Kim, K. T.
    Youn, H. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 254 - 255